Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 11;399(10342):2227-2242.
doi: 10.1016/S0140-6736(22)00470-6. Epub 2022 May 6.

Chronic obstructive pulmonary disease

Affiliations
Review

Chronic obstructive pulmonary disease

Stephanie A Christenson et al. Lancet. .

Abstract

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity, mortality, and health-care use worldwide. COPD is caused by exposure to inhaled noxious particles, notably tobacco smoke and pollutants. However, the broad range of factors that increase the risk of development and progression of COPD throughout the life course are increasingly being recognised. Innovations in omics and imaging techniques have provided greater insight into disease pathobiology, which might result in advances in COPD prevention, diagnosis, and treatment. Although few novel treatments have been approved for COPD in the past 5 years, advances have been made in targeting existing therapies to specific subpopulations using new biomarker-based strategies. Additionally, COVID-19 has undeniably affected individuals with COPD, who are not only at higher risk for severe disease manifestations than healthy individuals but also negatively affected by interruptions in health-care delivery and social isolation. This Seminar reviews COPD with an emphasis on recent advances in epidemiology, pathophysiology, imaging, diagnosis, and treatment.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests SAC reports grant funding paid to her institution from the National Institutes of Health (NIH) and Merck; consulting fees paid from AstraZeneca, GlaxoSmithKline, and Glenmark Pharmaceuticals; payment and honoraria paid from AstraZeneca, Sanofi/Regeneron, Genentech, and Sunovion; and participation in advisory boards or Data and Safety Monitoring Boards (DSMBs) for AstraZeneca, GlaxoSmithKline, Sanofi/Regeneron, and Glenmark Pharmaceuticals. BMS reports grants paid to their institution from NIH, Canadian Institutes of Health Research, Canadian Lung Association, Quebec Respiratory Health Research Network, and McGill University Health Centre Foundation, and leadership as director for the Centre for Outcomes and Research Evaluation of the McGill University Health Centre Research Institute. MB reports grants paid to their institution from AstraZeneca and Roche; consulting fees paid to their institution from AstraZeneca and GlaxoSmithKline; honoraria paid to their institution from AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline; and participation in advisory boards or DSMBs with fees paid to their institution from AstraZeneca and GlaxoSmithKline. NP reports research funding paid to their institution from NIH and CSL Behring, and participation in advisory boards for CSL Behring and Pharmacosmos.

MeSH terms

LinkOut - more resources